By Michael Dabaie

Tandem Diabetes Care Inc. shares rose 4.2% to $122.70 in premarket trading after the company said the U.S. Food and Drug Administration cleared bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app.

The insulin delivery and diabetes technology company said the updated mobile app is designed to allow t:slim X2 insulin pump users to program and cancel bolus insulin requests through compatible smartphone.
“This FDA clearance further validates our commitment to innovation and the diabetes community by providing one of the most requested feature enhancements,” Chief Executive John Sheridan said. “With the improvements in diabetes management provided by Tandem’s Control-IQ technology, giving a meal bolus is now the most common reason a person interacts with their pump, and the ability to do so using a smartphone app offers a convenient and discrete solution.”
Write to Michael Dabaie at michael.dabaie@wsj.com